Summary
of Third Meeting
January 13-14, 2005
Ronald
Reagan Building and International Trade
Center
Washington, DC
The
Secretary’s Advisory Committee on
Heritable Disorders and Genetic Diseases
in Newborns and Children was convened
for its third meeting at 9:00 a.m., Thursday,
January 13, 2005, in the Rotunda Ballroom,
Ronald Reagan Building and International
Trade Center, Washington, D.C. The meeting
was adjourned at 2:20 p.m., Friday, January
14, 2005. In accordance with the provisions
of Public Law 92-463, the meeting was
open for public comments from 1 p.m. to
2:00 p.m. onFriday, January 14, 2005.
HHS
Welcome and Opening Remarks
Dennis Williams, Ph.D.,
M.A.
Deputy Administrator
Health Resources and Services Administration
(HRSA)
Dr.
Williams welcomed members of the Advisory
Committee on Heritable Disorders and Genetic
Diseases in Newborns and Children (the
Committee) and conveyed the greetings
of Secretary of Health and Human Services
(HHS) Tommy Thompson and HRSA Administrator
Elizabeth Duke. He noted that HHS Secretary
Tommy Thompson would soon leave his post
and former Utah Governor Mike Leavitt
would assume the leadership. Dr. Williams
commended Secretary Thompson's leadership
on issues that relate to the welfare of
the nation's mothers and children and
thanked Dr. Howell and Dr. Peter van Dyck,
HRSA Associate Administrator for Maternal
and Child Health (MCHB), for their leadership
on the Committee. In addition, he welcomed
the newest member of the C ommittee, Dr.
Joseph Telfair.
Dr.
Williams emphasized that HHS and HRSA
value the work of the Committee to assure
that all children receive quality care
in all States. The Committee will evaluate
many critical issues surrounding newborn
screening programs including: opportunities
for research; information systems to evaluate
long-term health outcomes of infants identified;
surveillance systems to evaluate newborn
screening programs; the Regional Collaboratives
established this past year by HRSA’s
MCHB; financing of newborn screening programs;
and new technologies, such as tandem mass
spectrometry (MS/MS). Dr. Williams and
others at HRSA look forward to the Committee’s
recommendations on how to improve newborn
screening services nationwide and are
very confident that the Committee’s
knowledge and expertise will help them
recommend guidelines to Secretary Thompson's
successor that will greatly benefit children
and their families across the United States.
Committee
Business
R. Rodney Howell, M.D.
Chair, Advisory Committee on Heritable
Disorders and Genetic Diseases in Newborns
and Children (ACHDGDNC)
Dr.
Howell thanked Dr. Williams and the leadership
at MCHB for their support provided
to the Committee and his appreciation
for the work of Committee members.. The
first item of business was the unanimous
approval of the minutes from the 2nd
meeting of the Committee, September 22-23,
2004. Next, Dr. Howell reviewed the agenda
for the 2-day meeting, which focused on
Newborn Screening Program Infrastructure
and will include presentations on Data
Management Programs and the HRSA funded
Regional Genetics and Newborn Screening
Collaboratives. Recommendations from
the report produced by the American College
of Medical Genetics for HRSA were also
to be discussed.
Dr.
Howell introduced, the new Committee member,
Dr. Joseph Telfair, representing the Secretary’s
Advisory Committee on Genetics, Health,
and Society.
State
of the States Update
Bradford Therrell, Ph.D.
Director
National Newborn Screening and Genetics
Resource Center
Dr.
Therrell gave an update on newborn screening
activities in the States. He referred
to slides that showed the expansion of
screening panels due to the implementation
of MS/MS technology. Dr. Therrell noted
that the Tables of data presented are
only as comprehensive as how extensively
States agree to voluntarily report information.
He urged the Committee to further discuss
the issue of mandated reporting.
Committee
members posed a number of questions. Dr.
Boyle asked whether most States are required
to report on newborn screening to their
State health departments, and submit aggregate
data to the Federal level. Dr. Therrell
responded that Title V of the Social Security
Act (Maternal and Child Health Block Grant)
requires reporting for some disorders.
State newborn screening programs may develop
data and report it for their own quality
control programs. This inconsistency makes
it difficult to keep up with the status
of State programs. There is no requirement
for the States currently to report conditions
to any group.
Discussion
indicated that disorders are not counted
consistently in the same way across States.
Dr. Therrell indicated the impetus to
use higher numbers is driven, in part,
by competition for control of the newborn
screening program or for direct marketing
to parents. With the competitiveness
among States and among private laboratories
for how many conditions are tested, it
would be helpful for the Committee to
arrive at some generally agreed upon way
to count conditions. Dr. van Dyck and
a small group are going to produce a piece
on this issue for the Committee before
the next meeting to spur further thought
on this issue. Dr. Howse said the March
of Dimes believes that the list of tests
in the ACMG report is adequate and a good
starting point.
Dr.
Therrell led the next discussion on the
major incentives for expanded screening.
In the next two to three years, consumer
and professional interest and advocacy
will continue through the press, legislature,
and the health departments. Dr. Becker
commented Ohio experienced pressures to
expand its newborn screening program that
would include disorders that can be screened
using MS/MS technology. Because Ohio
initially focused its attention on MS/MS
disorders, the State is now adding cystic
fibrosis, biotinidase deficiency and congenital
adrenal hyperplasia (CAH), which require
technology that is not MS/MS driven. Dr.
Rinaldo observed that the main driver
of expanded screening is States feel they
are behind, and their constituencies realize
their children or babies are not being
offered a perceived national standard
of care. Dr. Rinaldo then suggested, the
issue of counting disorders is a bit exaggerated—and
the serious consequence of continued thinking
along these lines is to hijack the concept
of quality.
Dr.
Telfair inquired about the extent of State
data collected on the outcome of infants
who test positive and the effectiveness
of follow-up. Dr. Therrell replied, follow-up
is an issue, as some States do short-term
follow-up adequately and report that information;
but long-term follow-up is not tracked
as completely.
The
topic of subcommittee structure concluded
the discussion. Dr. Boyle asked Dr. Therrell
to provide some guidance to the Committee
on subcommittee structure, such as pressing
issues and how the Committee can be most
helpful in that regard. In addition, Dr.
van Dyck stated that he will present a
priority list of issues related to newborn
screening, developed by staff that might
feed into the deliberations about subcommittees.
Newborn
Screening Program Infrastructure; Research
and Service Delivery
Research - The NIH Office
of Rare Diseases: Opportunities for Collaborative
Research and Development Activities
Stephen Groft, Pharm.D.
Director
Office of Rare Diseases
National Institutes of Health
Dr.
Groft presented an overview of the activities
of the NIH Office of Rare Diseases (ORD),
including its newly established Rare Diseases
Clinical Research Network and Data and
Technology Coordinating Center. ORD was
established in 1993 without any legislative
mandate. With the assistance of patient
advocacy groups, in 2002 legislation was
passed that mandated certain activities
within the office; the emphasis was clinical
research. With this mandate came an increase
in ORD’s budget; the office is currently
funded at the level of $15.5 million.
The
Rare Diseases Act of 2002 (Public Law
107-280) established ORD statutorily within
the Office of the Director of NIH and
specified the following responsibilities
for ORD: (1) recommend research and public
education agendas at NIH; (2) promote
coordination and collaboration of rare
diseases activities; (3) develop an information
center on rare diseases; (4) prepare a
biennial report to Congress on rare diseases
research and education activities, with
an emphasis on future research activities;
and (5) prepare an annual report to Congress
on research advances in rare diseases.
ORD’s biennial report is available
online at http://rarediseases.info.nih.gov.
ORD
works with NIH institutes and centers
to support: (1) an extramural research
program, a Rare Diseases Clinical Research
Network; (2) an intramural research program,
the ORD/National Human Genome Research
Institute; (3) a scientific conferences
program; (4) a Trans-NIH Working Group
on Rare Diseases Research; and (5) a Genetic
and Rare Diseases Information Center.
Committee
members applauded the development of ORD’s
Rare Diseases Clinical Research Network
It was suggested that ORD establish links
with traditional newborn screening programs
in its request for applications to obtain
a repository of samples (e.g., DNA, serum,
tissues) that could be utilized for its
clinical investigators, and vice versa.
Dr.
Boyle concluded that the Rare Disease
Clinical Research Network provides an
opportunity to learn more about the natural
history and impact of clinical treatment
on many disorders that are in the purview
for newborn screening. Dr. Boyle further
indicated that it appears that additional
infrastructure is not needed in the area
of research. Dr. Groft noted that a lot
of the infrastructure already exists,
but the challenge is to use it appropriately.
ORD is already working closely with the
NIH Institutes and with the Genetics Services
Branch of the MCHB, HRSA to interconnect
and share infrastructure.
Service
Delivery –Infrastructure: Regional
Genetics and Newborn Screening Collaboratives
Michele Lloyd-Puryear, M.D., Ph.D.
Chief
Genetics Services Branch
Maternal and Child Health Bureau
Health Resources and Services Administration
Dr.
Lloyd-Puryear presented
the service delivery component of the
newborn screening infrastructure—namely,
the new network of seven, Regional Genetics
and Newborn Screening Collaboratives,
and the National Coordinating Center at
ACMG, Bethesda, Maryland. The HRSA grants
were announced by HHS Secretary Tommy
Thompson, in December 2004.
The
network of Regional Genetics and Newborn
Screening Collaboratives was created in
response to the Children's Health Act
of 2000 (Public Law 106-310). That law
directs the Secretary of Health and Human
Services to award grants to “enhance,
improve, or expand the ability of State
and local public health agencies to provide
screening, counseling, or health care
service to newborns and children having
or at risk for heritable disorders.”
In appropriations language, Congress asked
HRSA to take the lead in implementing
this Heritable Disorders Program.
MCHB,
the Federal entity with the most responsibility
for newborn screening programs, began
by creating this Committee in 2003. One
of the functions of the Committee (specified
by legislation and in the Committee’s
charter) is to provide advice and recommendations
concerning grants and projects authorized
under the Heritable Disorders Program.
In
fiscal year 2004 appropriations, Congress
specified that $2 million from the SPRANS
(“Special Projects of Regional and
National Significance”) portion
of the Maternal and Child Health Block
Grant (Title V of the Social Security
Act) should be applied to the Heritable
Disorders Program. HRSA matched that
amount with an additional $2 million.
MCHB is currently working with a total
budget of $4 million for the Heritable
Disorders Program. Under Federal legislation,
funds for this program can be used to
establish a fairly encompassing list of
programs related to newborn screening,
but the focus is primarily on the development
of the service infrastructure. MCHB is
using the Regional Collaboratives as a
methodology to begin implementation of
the Heritable Disorders Program. It is
hoped that by fostering collaborative
efforts, the Regional Genetics and Newborn
Screening Collaboratives will improve
States’ newborn screening capacity
and equalize the distribution of genetic
resources within regions.
Dr.
Lloyd–Puryear gave an overview of
the activities proposed by each of the
Regional Genetics and Newborn Screening
Collaboratives. Within the first 3 years,
MCHB expects each of the seven Regional
Collaboratives to achieve specified endpoints:
Year 1, development of a regional coordinating
plan, practice models for optimal diagnosis
and follow-up and management; Year 2,
development of a strategy to implement
practice models; and Year 3, demonstration
of public-private regional and collaborative
relationships that represent a variety
of health systems organizations—community
health centers, health care insurers,
health maintenance organizations, State-based
primary care organizations, and academic
institutions—for all States within
the region.
The
National Coordinating Center will focus
on minimizing duplication of efforts,
identifying best practices developed by
the regions, and maximizing interregional
collaboration. To date, the National Coordinating
Center has proposed the following: (1)
develop networks of centers of genetic
services with primary care providers;
(2) facilitate data information exchange
and collaborate with the NIH’s rare
disease centers and the CDC’s genomics
centers; and (3) work with organizations
such as the American Academy of Pediatrics
and the Academy of Family Physicians to
address the development of codes in the
Current Procedural Terminology, and with
organizations such as the Joint Commission
on the Accreditation of Healthcare Organizations
to bring uniformity of practice within
hospitals for newborn screening programs
regarding for blood samples procedures
for newborn screening; and (4) encourage
information-sharing projects (e.g., through
telemedicine).
MCHB
and the National Coordinating Center examined
the proposals submitted by the seven funded
Regional Genetics and Newborn Screening
Collaboratives to identify several areas
of shared need, as follows:
-
Communication methodologies, ranging
from videoconferencing to telemedicine,
setting up practice models and practice
relationships with genetics networks
and the use of interstate satellites;
-
Information management, including web-based
clinical management systems suitable
for telemedicine or even for satellite
clinics;
-
Reimbursement in general, across State
lines or over a long distance (e.g.,
telephone consultation);
-
Evaluation methodologies;
-
Expansion of newborn screening, as well
as the expansion of the service infrastructure
needed to provide follow-up services
to newborns that test positive;
-
Specific regulation and legislation
to allow interstate licensing for liability
concerns across State borders;
-
Financing, not just for the expansion
of newborn screening, including the
expansion of the newborn screening service
infrastructure and development of new
paradigms of working relationships;
-
Expanding access to genetic services
(e.g., via by training geneticists and
primary care; increasing the diversity
of trainees; and via a mechanism to
more systematically address the geographic
maldistribution of services).
Dr.
Lloyd-Puryear noted that the National
Coordinating Center for the network of
Regional Genetics and Newborn Screening
Collaboratives has proposed the following
coordinating partners: the National Conference
of State Legislators, the American Academy
of Pediatrics, the Association of State
and Territorial Health Officials, and
the Genetic Alliance. Dr. Dougherty wondered
if the National Coordinating Center was
open to more suggestions for coordinating
partners, such as American College of
Obstetricians and Gynecologists and American
Hospital Association, which Dr. Lloyd-Puryear
welcomed. Dr. Howell commented that the
March of Dimes Birth Defects Foundation
is another obvious candidate.
The
presentation raised several questions
and comments. Dr. Brower asked whether
carrier screening for parents and prenatal
testing fall within the mandates of MCHB.
Dr. Lloyd-Puryear replied, both fall
within their mandates but there is no
specific legislation for prenatal screening.
Carrier screening would be generally considered
part of the diagnostic work-up for an
infant identified as screen positive in
a newborn screening program and its parents.
In
reply to Dr. Howell’s inquiry about
communication among the Regional Genetics
and Newborn Screening Collaboratives,
Dr. Lloyd-Puryear said, an ongoing communication
process is very important and various
mechanisms will be used. Also, the National
Coordinating Center will bring resources
to the effort. Dr. Lloyd-Puryear added,
the regional grants awarded to the Regional
Genetics and Newborn Screening Collaboratives
are not ordinary grants. They are “cooperative
agreements’ that require a willingness
to collaborate with MCHB and the National
Coordinating Center.
Dr.
Groft, suggested that the Rare Diseases
Clinical Research Network join forces
with the network of Regional Genetics
and Newborn Screening Collaboratives.
The purpose is to see how they can intersect
to make activities more effective and
to make knowledge of each other's activities
better known to the entire community.
Dr. Telfair and other committee members
agreed that the relationship would provide
an effort to further ensure that the results
from research are translated into clinical
practice.
Dr.
Becker inquired about HRSA mechanisms
that would enable the Committee to provide
oversight of the network of Regional Genetics
and Newborn Screening Collaboratives,
with respect to outcomes for best practices,
standardizing uniform panels of conditions
across regions, and provision of services
to underserved populations. Dr. Lloyd-Puryear
said she presented the legislation to
remind the Committee that one of its charges
is to advise on the Heritable Disorders
Program. The network of Regional Genetics
and Newborn Screening Collaboratives does
not address all aspects of the legislation,
but the implementation of the Heritable
Disorders Program is the first effort.
MCHB also views the network of Regional
Genetics and Newborn Screening Collaboratives
as an opportunity to pilot standards development,
and it will bring products back from the
network to the Committee for review.
Dr. Dougherty questioned the resources
for the evaluation process. Dr. Lloyd-Puryear
remarked, there is an evaluation component
within each Collaborative, but with a
$4 million limit, there is no funding
for overall evaluation of the Regional
Genetics and Newborn Screening Collaboratives
initiative. Performing such an evaluation
would cost an estimated $500,000/year.
The discussion resulted in the following
Committee Motion:
MOTION
#1: The Committee recommends that there
be an evaluation of the Regional Collaboratives
Program based on a well-developed evaluation
plan.
This
motion was made with the understanding
that there would be a plan for the evaluation
and then funding would be based on the
plan. As an additional step, the staff
would provide the Committee with the plan
for what would be evaluated that would
assist the Committee in building this
recommendation for what would be evaluated
and how the funds would be used for an
evaluation. The motion passed unanimously.
Newborn
Screening Program Infrastructure: Evaluation
and Tracking
Database for the Long-Term Follow-up
of Infants Identified by MS/MS Newborn
Screening
Judith Tuerck, R.N., M.S.
Assistant Professor
Oregon Health and Sciences University
Child Development and Rehabilitation Center
Ms.
Tuerck gave an overview of the justification,
development and effectiveness of CDC’s
database system for evaluating long-term
health outcomes in newborns identified
by MS/MS screening as having metabolic
disorders. The long-term follow-up of
newborns who test positive in newborn
screening tests begins once the child
has been diagnosed and placed on a treatment
regimen—and ideally, would continue
throughout the life of an individual,
regardless of where in the country the
individual is receiving treatment. As
experience with neonatal galactosemia
illustrates, some disorders and conditions
thought to be benign and easily treated
in early childhood may in fact have serious,
long-term complications.
In
1992, the Council of Regional Networks
for Genetic Services Newborn Screening
Guidelines recognized the need for
long-term follow-up of newborns diagnosed
with heritable disorders and genetic diseases.
It is important to do long-term follow-up
to learn about: incidence/prevalence
of heritable and genetic disorders; morbidity/mortality
from such disorders; efficacy of treatment;
natural history of disease; psychological
impacts of disease; barriers to care;
and the cost of care for such disorders.
Long-term follow-up tracking is less than
adequate, with little pooling of health
outcomes information among the treatment
centers around the United States. Also,
any given treatment program in the United
States has so few patients that the patient
sample population is too small to make
data analysis substantive. Now that States
are implementing MS/MS screening, there
is an opportunity to collect national
long-term follow-up data on children identified.
This, however, requires a tool for data
collection, and a system to pool data
to share nationally and internationally.
In
2002, CDC awarded a grant to Oregon and
Iowa to develop a tool for collecting
long-term follow-up data on newborns diagnosed
with fatty acid oxidation disorders, organic
academia disorders and urea cycle disorders.
That database system is now implemented
in point-of-care clinics in Oregon, Iowa,
and Idaho. It is being used to collect
long-term follow-up data on newborns diagnosed
with 26 disorders and their siblings.
Ms.
Tuerck reported the data shows that the
incidence of MS/MS disorders is 1:5,300
in Iowa, 1:4,300 in Oregon, and 1:2,300
in Idaho (as compared with 1:15,000 in
Hawaii). Also, the data suggest that a
number of newborns in Oregon, Iowa, and
Idaho were identified through the second
screening test, which is routine in Oregon,
as having the following metabolic disorders
- carnitine transport disorders, CPT1,
arginase deficiency, homocystinuria, and
VLCAD (very-long-chain acyl-CoA dehydrogenase
deficiency). (Other cases identified on
the second test appear to be related to
cutoff levels.) Ms. Tuerck remarked that
it appears that not all metabolic disorders
will be identified in a sample taken from
a newborn in the first day or so.
The
database system has the potential for
other data collection applications, including
the tracking of long-term follow-up of
newborns with a variety of other heritable
disorders and genetic diseases; evaluation
of the efficacy of screening for such
disorders; and evaluation of the efficacy
of treatment. It may be possible to develop
a National Long-Term Follow-up Center
for Metabolic Disease (similar to the
cystic fibrosis and the national cancer
databases), to pool data from multiple
centers for national analysis of either
epidemiology or collaborative clinical
studies to expedite the identifying of
benefits and/or complications. Moreover,
the database technology could be enabled
to: implement automatic data collection
from billing offices and laboratories;
and read electronic medical records. The
Northwest will consider the feasibility
of implementing the database at other
States in the region. The costs of collecting
data, pooling and analyzing data with
other centers, and system adaptability
for different functions will be evaluated.
The
project will investigate the use of an
informed consent process to allow for
more in depth data collection. A goal
is to get metabolic centers to use the
database system to provide data to the
State or a national data pool. Additional
funding would allow for the continued
collection of data on these same children
and any other children born.
Dr.
Howell remarked he was surprised and alarmed
by the positive second test results, because
most States in the country do not do a
second test. He asked whether there was
confirmation that the first tests were
negative. Ms. Tuerck replied that the
cards were analyzed at outside labs using
those laboratories’ cutoffs and
technology, and those labs verified that
the tests were negative. Oregon offers
a second test at approximately 2 weeks
of age. Dr. Rinaldo said that Ms. Tuerck
was making a very strong statement about
the need for a second test. It is important
to document the analytical performance
in the analysis of the first test because
the first test could have had an inadequate
cutoff. In addition, the data should be
made available for peer review.
Ms.
Tuerck added that labs are struggling
with cutoffs, and reported that there
will be a subset of children with these
diseases who will not necessarily be abnormal
in the first day or so of life. This is
not news for disorders, such as homocystinuria
and thyroid disease. Dr. Howell concluded
that the Committee should continue to
discuss: (1) the need for a second screening
test; and (2) what cutoff points should
be used for specific tests. Discussion
indicated eight States currently mandate
a second screen on every baby; three States
recommend a second screen and have greater
than 80 percent compliance. States use
data primarily on hypothyroidism and CAH,
and an occasional galactosemia to point
to the need for a second screen.
Newborn
Screening Program Infrastructure: Integrated
Information Systems
David Ross, Sc.D.
Director
Public Health Informatics Institute
Dr.
Ross described the
status and near-term future of integrating
clinical information systems with public
health information systems to improve
the coordination of care for children.
The Public Health Informatics Institute
(PHII) believes that public health agencies
and health care providers should be pushed
to integrate their information systems
so that providers and parents can obtain
complete and accurate data sets about
children in a timely way.
Dr.
Ross focused on four topics: (1) the proposed
National Health Information Network (NHIN)
and related efforts; (2) problems in obtaining
information about a child’s health;
(3) ongoing efforts to integrate health
information systems, including pediatric
electronic health records; and (4) the
potential for improving health outcomes
by integrating child health information
systems.
This
is a time of change and transformation
for health care and public health. The
Office of the Secretary will focus on
the development of NHIN—that would
allow patients, physicians, hospitals,
public health agencies, and other authorized
users across the nation to share clinical
information electronically in real-time
(under stringent security, privacy, and
other protections). The hope is that the
NHIN will be built over time, largely
by the private sector, by linking regional
clinical information systems through regional
health information organizations (RHIOs)
across the country. Several RHIOs and
regional information systems already exist
around the country, and more should be
developed in the future. CDC has been
working on standards for a Public Health
Information Network (PHIN) that could
potentially be integrated into the NHIN.
Currently,
health information systems are not sufficiently
integrated to allow health care providers
and parents to obtain comprehensive information
about a child at the point of care. Often
children found to have disorders or hearing
loss during newborn screening are not
followed-up and treated in a timely manner
because pediatricians lack the results
of newborn screening tests. Dr. Ross believes
this problem can be solved as a part of
the transformation of the U.S. health
care information system that is beginning
to take place with the move to develop
the NHIN.
For
the last few years, PHII has been working
in collaboration with MCHB in the realm
of integrating child health information
systems to enable authorized users of
the systems to see “at-a-glance”
comprehensive information about a child’s
health status and health needs. Dr. Ross
believes there are four programs/systems
for the newborn period that should be
considered priorities for developing integrated
child health information systems: (1)
immunization programs; (2) newborn dried
blood spot screening programs; (3) early
hearing detection and intervention programs;
and (4) vital records registration systems.
PHII is working with a number of State
public health agencies to define an integrated
child health information system and to
understand how to design, build, and implement
such systems. This work led to the 2003
publication by MCHB and All Kids Count
(AKC)/PHII, Integration of Newborn
Screening and Genetic Service Systems
with Other MCH Systems—A Sourcebook
for Planning and Development—online
at http://www.phii.org/publications.html.
PHII
is working also with MCHB on the principles
and core functions of integrated systems,
and will release a document in the near
future. It believes that no clinical or
public health information system should
exist without performance metrics and
is developing and testing such performance
measures. MCHB is providing funding through
a cooperative agreement with PHII to build
a community of practice composed of public
health program staff and private providers
to understand what integrated child health
information systems can and cannot offer.
A
new supplement to the Journal of Public
Health Management and Practice summarizes
recent progress toward developing integrated
child health information systems, and
is available from the PHII in Decatur,
Georgia, or on its website at http://www.phii.org/Files/JPHMPH%20Supplement.pdf.
Dr. Ross added a goal of
the AAFP is to have at least half
its members using electronic health records
by 2006 and a majority of AAP members
recently endorsed the adoption of electronic
health records within 5 to 10 years.
Dr.
Ross concluded by stating that there is
a considerable amount of health information
system activity currently going on. Most
of it is focused on clinical systems;
some of it is focused on public health
systems; and a little is focused on integrating
the two. Most activity is geared to programmatic
rather than research functions, so it
is important for researchers to be involved
in the process to ensure that the health
information systems are developed meet
the needs of researchers. It is too
early to demonstrate the impact of integrating
child health information systems, but
it is rational to anticipate that providing
more information to users will lead to
better outcomes.
Dr.
Edwards asked Dr. Ross how the need for
information in newborn screening could
be reconciled with the need for confidentiality
in an electronic information system.
Dr. Ross replied that electronic technologies
address systems’ security indicating
who looked at electronic records, when,
and potentially what they did with the
information—but it will take time
to become comfortable with how much less
than perfect security we can tolerate.
We ultimately may reach a point where
people say there is more to be gained
in sharing information than lost in keeping
information isolated. Information technology
can solve problems, but the social dialogue
about this is not complete yet. Dr. Becker
noted that from the States' perspective,
the Health Insurance Portability and Accountability
Act of 1996 (HIPAA) does not prohibit
the reporting of public health mandated
data.
Dr.
Ross highlighted Rhode Island which has
had a pediatric public health tracking
system called KIDSNET for a decade or
more. Furthermore, the State recently
received a contract from the AHRQ to enter
into collaboration with an RHIO in which
the Rhode Island Department of Public
Health participates. The KIDSNET data
system will be added to the region’s
integrated data system, so private physicians
in various hospitals and private practices
will be able to gain access to data from
KIDSNET. Rhode Island is an example of
a State where providers will eventually
be able to get a complete and up-to-date
record on a child.
Committee
Business - Update on the American College
of Medical Genetics Report to HRSA
Peter van Dyck, M.D., M.P.H.
Associate Administrator
Maternal and Child Health Bureau
Health Resources and Services Administration
(HRSA)
Dr.
van Dyck reported on the status of the
ACMG report to HRSA on newborn screening.
The Committee reviewed a very early draft
of the report at its September 2004 meeting
and directed that when the ACMG report
had been fully edited and completed, it
should be sent to the Secretary, with
a cover letter from Committee Chair, Dr.
Howell, transmitting the report with the
Committee’s recommendation of the
report. The Committee further directed
that the Public Comments from the September
meeting be appended to Dr. Howell’s
transmittal letter. The report is now
final.
Dr.
van Dyck said, HRSA is comfortable appending
this final version of the ACMG report
to the letter from Dr. Howell recommending
the report to the Secretary. In comparison
to the preliminary report reviewed by
the Committee in September, this later
version has been substantially amplified
with data. In addition, the final version
includes: a 200-page appendix with a two
to three page description of every one
of the 80 or 90 disorders discussed in
the report; a discussion of the treatment;
availability and cost, efficacy of treatment;
benefits of early intervention and early
identification; prevention of mortality;
diagnosis; acute management; simplicity
of therapy for each disorder; and literature
cites. It also includes each disorder’s
score and recommendation with regard to
whether a test for the disorder be contained
in a core panel or not. Dr. van Dyck believes
that this is the first time that this
kind of full information has been available
ever for even a handful of these conditions.
HRSA
is now working on getting departmental
permission to release the ACMG report
on newborn screening for public comment.
After the report’s release, there
will be about 60 days for a public comment
period and for the Committee to comment
on the report again. HHS will then take
public comments and inputs from the Committee
and other sources, and try to put them
together into a recommendation from HHS.
Several
Committee members questioned about when
the final version of the ACMG report would
be made available to the public. Dr. Howse
emphasized that the March of Dimes would
like the report in the public domain as
soon as possible so people can comment
on it. Dr. van Dyck explained, the report
would come out for public comment as soon
as they were able to gain departmental
clearance, and hoped the release would
occur within days/weeks. The report will
be released online at the websites of
the Committee and MCHB. Also, it will
be mailed to organizations by request
or interest. There may be a 60-day comment
period, but it might be slightly longer
or shorter. An audience participant questioned
whether there was a change from a 30-day
public comment period to a 60-day comment
period, referring to the minutes from
the Committee’s September 2004 meeting
(p. 32):
"It
was decided, given the strong interest
in forwarding the report to the Secretary
as soon as possible, the committee will
accept and recommend the report and forward
it to the Secretary immediately. There
will then be a 30-day period in which
electronic written forms from the public
will be collected and the committee will
form its comments and recommendations
and forward them to the Secretary with
appended public comments."
Dr.
van Dyck said, the Appendix to the ACMG
report sent to the Secretary with Chairman
Howell’s transmittal letter are
the public comments from the September
meeting with any additional comments received
in the 30 days following the September
meeting, per HRSA’s interpretation
of the Committee’s discussion.
Dr. Howell noted some confusion and differing
expectations about what was to be done
with the ACMG report following the September
meeting. The key thing for the Committee
now is to clarify its steps and move forward.
After
considerable discussion, the Committee
voted on and unanimously approved
the following motions related to the disposition
of the final ACMG report to HRSA on newborn
screening:
MOTION
#1: “The Committee directs that
the ACMG report be sent immediately to
the Secretary of HHS under Chairman Howell’s
signature on behalf of the Advisory Committee
on Heritable Disorders and Genetic Diseases
in Newborns and Children.
-
This motion was made with the understanding
that the report had already been recommended
by the Committee at its September 2004
meeting. Consequently, the letter to
the Secretary from Dr. Howell should
say that the Committee is recommending
the report to the Secretary.
-
b. The word “immediately”
was clarified to mean as soon as possible
under HRSA regulations and the law.
MOTION
#2: The Committee recommends that the
ACMG report be released into the public
domain as soon as possible for review
and comment.
MOTION
#3: The Committee recommends that the
Committee review the ACMG report and make
comments as a Committee in the same time
frame as the public comments.
MOTION
#4: The Committee requests an opportunity
to review public comments on the ACMG
report and to provide advice to the Secretary
on those public comments.
January
14
Newborn
Screening Program Infrastructure: Data
Collection
National Newborn Screening Data Initiatives
Bradford Therrell, Ph.D.
Director
National Newborn Screening and Genetics
Resource Center
Dr.
Therrell gave an overview of the NNSGRC’s
online National Newborn Screening Information
System (NNSIS)—an important component
of the data and surveillance infrastructure
for newborn screening. The development
of the online NNSIS took about 4 years.
The
NNSGRC transitioned to the online NNSIS
January 1, 2005. All but one State participates
in the NNSIS. Dr. Therrell showed Committee
members some screens from the NNSIS Website,
and described how to use the system for
data entry and generating reports. It
will be made available to the public through
links through the NNSGRC website (http://genes-r-us.uthscsa.edu/).
Dr.
Therrell reiterated there are several
challenges with the NNSIS: (1) data reporting
on newborns are neither mandated nor a
defined program responsibility in most
States; (2) the national data set is the
result of consensus amongst newborn screening
programs, and not proscribed; (3) data
definitions are not consistent from one
State newborn screening program to another;
(4) staff shortages and turnover affect
data entry into the system; (5) the quality
of the data from some State programs is
difficult to validate; (6) maintaining
data on babies moving into a State or
living on the border is often problematic;
and (7) obtaining accurate data on military
births is difficult.
Several
Committee members applauded the development
and implementation of the NNSIN by the
NNSGRC, saying it would generate a tremendous
amount of interest and activities for
improvements in newborn screening and
research. Committee members indicated
they would support the Committee (or its
subcommittee) involvement in the area
of information management for newborn
screening programs.
Dr.
Becker acknowledged that the Ohio Bureau
of Public Health Laboratories is using
the NNSIS and believes the system will
be helpful, but he doubts that States
will replace their internal databases
with the NNSIS. Dr. Becker outlined three
challenges for the States with respect
to participating in the NNSIS. States
may need resources to: (1) help States
with separate laboratory and follow-up
services that use separate databases to
communicate with the NNSIS; (2) develop
mechanisms for private laboratories to
report data to the NNSIS (e.g., as a pass
through to the State or directly); and
(3) most importantly, to ensure the quality
of data reported (e.g., education and
training of data entry personnel). Dr.
Therrell addressed some of the challenges:
(1) NNSIS has separate menus for laboratory
and follow-up, so States with separate
laboratory and follow-up services should
have no problems; (2) NNSIS has built
into the system a way for the private
laboratories to download data for the
State.
Dr.
Rinaldo asked Dr. Therrell what the Committee
might do to help with the NNSIS. Dr.
Therrell emphasized Committee support
for a national mandate—for States
to report newborn screening data, including
a mandate to report at certain times,
in certain ways, and an agreement on the
need for the data and the definitions.
Dr. Rinaldo thinks this could be addressed
by one of the subcommittees. Dr. Boyle
believes that the reporting and the responsibility
for follow-up reside at the state level,
and that mandating reporting of data from
State programs is not at the Federal level,
rather NNSGRC should be a facilitator
to help develop standards, centralize
reporting to compare data across States,
and help States with program monitoring
to make State newborn screening programs
work more efficiently and appropriately.
Dr.
Becker agreed, but suggested it would
be helpful to have a national reporting
process for newborn screening, perhaps
patterned on the successful model of the
national infectious diseases system, where
the CDC, the Association of State and
Territorial Health Organizations, and
especially the Council of State and Territorial
Epidemiologists produce lists of infectious
diseases that all States should be reporting.
Dr. Therrell clarified that he was mainly
talking about expanding reporting requirements
under Title V (Maternal and Child Health
Block Grant).
Turning
to the utilization of the NNSIS, Dr. Telfair
asked Dr. Therrell whether anyone at NNSGRC
has begun to analyze how the information
in the NNSIS is used by States for decision
making, or if not by the States, then
by others who are trying to make decisions.
Dr. Therrell replied that they hear anecdotally
how States are using the information in
the NNSIS, but suggested a need for a
more systematic analysis. Dr. Therrell
said the NNSGRC collates data based on
what the States indicate would be useful
to them and to the public; they had not
considered the use of the data by other
entities.
Dr.
Dougherty asked whether data from the
NNSIS could be used to look at the question
of how many babies who get a second screening
test are confirmed with secondary screening,
and whether such analysis is part of the
mandate of the NNSGRC. Dr. Therrell said
although such analysis is not part of
the center’s mandate, some people
have already used the screening data for
analysis such as looking at second tests
in the newborn screening program. Dr.
Rinaldo asked about the potential for
using the NNSIS data for quality improvement
initiatives more generally. Dr. Therrell
replied that some States have used the
data in their own quality assurance efforts,
but the decisions are made on a state-by-state
basis. There is no mandate for the NNSIS
data to be used for quality improvement
initiatives. Dr. Hawkins asked how the
NNSGRC collects newborn screening data
on military families and families that
travel overseas. Dr. Therrell is aware
that a lot of the different military bases
overseas have mechanisms in place to send
newborn blood spot samples back to States
(e.g., Colorado, Oregon, or Texas) to
perform the screen. U.S. citizens who
have babies abroad often have screening
services provided by a local in-country
program. Dr. Edwards asked whether the
NNSIS is a place where doctors can access
information about patients. Dr. Therrell
said that although he favors such a national
dataset, it’s not in the near future
due to privacy issues. The NNSIS obtains
gross data from the States that does not
link to identified patients.
Newborn
Screening Program Infrastructure: Surveillance
Birth Defects Surveillance Systems
Leslie Beres-Sochka, M.S.
Program Manager
Early Identification and Monitoring Program
New Jersey Department of Health and Senior
Services
Ms.
Beres-Sochka gave a presentation on State
birth defects and surveillance systems,
highlighting the New Jersey’s Special
Child Health Services Registry. This registry
now serves as a linchpin from the diagnosis
of a birth defect to the provision of
services for the child found to have a
birth defect.
Currently,
there are 38 operational birth defects
surveillance programs in the United States;
9 additional birth defects surveillance
programs are in the planning stages. Five
States have no birth defects program—a
situation CDC is trying to change. CDC
recently surveyed the States about their
ability to refer children found to have
birth defects to a service system. Of
the States that replied, 26 already had
a system in place, 17 were planning such
a system, and 3 had no plan for linking
the birth defect surveillance to the service
system. Among States that were linking
children with birth defects to the service
system, some were referring all children
with birth defects to services as New
Jersey does and some referred only children
with specific defects (e.g., neural tube
defects or cleft palate) to services.
The
Special Child Health and Early Intervention
Services Program, a component of New Jersey’s
Department of Health and Senior Services,
Ms. Beres-Sochka explained, has four organizational
units:
Early
Identification and Monitoring Program.
The Early Identification and Monitoring
Program is responsible for New Jersey’s
Special Child Health Services Registry,
which collects data on children with birth
defects and special needs. The registry
contains a confidential record of all
children with birth defects identified
in the first year of life. The registry
is allowed to use data from the State’s
electronic birth certificate database
to amend its data and for research. The
Early Identification and Monitoring Program
is also responsible for New Jersey’s
newborn hearing screening program.
Newborn
Screening and Genetic Services Program.
The Newborn Screening and Genetic
Services Program is responsible for screening
newborns. The Newborn Biochemical Screening
Follow-up Program provides information
on any newborn diagnosed case into the
Special Child Health Services Registry.
Of the 113,404 newborns screened in New
Jersey in fiscal year 2004, 6,395 were
referred for follow-up, and 3,458 had
abnormal results
Family-Centered
Care Program. The Family-Centered
Care Program is a case management program
for children with special health care
needs. The purpose of New Jersey’s
county-based case management program is
to help children access family-centered,
culturally competent, coordinated services
for children. More than 90% of the caseload
in this program is from direct referrals
from the Special Child Health Services
Registry. The registry tries to makes
a direct referral into the case management
program within 10 days (or sooner if need
be).
Early
Intervention Services Program. In
1993, New Jersey’s case managers—primary
care providers or other involved professionals—began
to serve as the single point of entry
for the Early Intervention Services Program.
The Special Child Health Services Registry
gives case managers the data to referral
to case management medical services, or
if the children require early intervention,
offer that immediately. Early intervention
is voluntary and requires parental consent
for participation. Any hearing loss makes
a child presumptively eligible for early
intervention.
New
Jersey‘s integrated system identifies
children with special needs in a timely
manner; most children with birth defects
are registered by the time they are 6
months old, so the link to services is
made very quickly. The framework for the
system is provided by separate laws and
rules for the birth defects registry,
the hearing screening program, and the
newborn blood spot screening program that
mandate not just the screening but also
the reporting to the Special Child Health
Services Registry. The organizational
structure in New Jersey, in which four
very important components of screening,
surveillance and services report to the
same agency (i.e., the Special Child Health
and Early Intervention Services Program),
facilitates communication. The integrated
system is both cost-effective and efficient.
Among the challenges the Special Child
Health Services Registry faces are funding
(currently provided by a variety of sources,
including HRSA and CDC, as well as by
the State and counties), ensuring confidentiality,
and coping with staff turnover at birthing
facilities and other health care providers.
Committee
members thanked Ms. Beres-Sochka for her
presentation and noted that the program
in New Jersey could serve as a model for
other programs. Dr. Howell commented that
Ms. Beres-Sochka’s figures indicated
that approximately 1 in 40 newborns screened
in New Jersey had an abnormal result—a
high figure. His recollection was that
Mississippi data presented at the Committee’s
previous meeting indicated that 1 in 300
had an abnormal result. Ms. Beres-Sochka
emphasized that that the data are provisional.
The final data may be closer to Mississippi’s
figures. Nevertheless, Dr. Howell noted,
the data clearly underline the importance
of the expanded programs the State has
in place.
Dr.
Dougherty asked whether the effectiveness
of the treatment and the parent satisfaction
with the case management, are being followed
at all. Ms. Beres-Sochka replied New Jersey’s
new electronic early intervention database
system will provide a systematic way to
track what treatments children are getting
and whether they are improving as a result
of those interventions. Dr. Howell affirmed
the importance of understanding the effectiveness
of treatment.
Mr.
Robertson inquired about New Jersey’s
definition of final case disposition.
Ms. Beres-Sochka replied that it is final
diagnosis. Once a newborn’s diagnosis
is confirmed, the child is referred to
services. Case managers keep the children
in case management until the day they
turn 22; after that, there is a process
in place for transitioning them to adulthood.
Dr.
Howse wondered if the conditions in New
Jersey’s screening panel relate
to the conditions recommended in the ACMG
report on newborn screening. She also
asked what New Jersey’s policy is
with respect to screening for secondary
conditions (i.e., conditions that are
detectable but cannot be treated). Ms.
Beres-Sochka replied that for secondary
targets, the State notifies the child’s
primary care provider and parents.
Ms.
Beres-Sochka clarified how the newborns
that are screened get into the case management
system: after the babies have been screened
in the blood spot program, they get reported
immediately through an electronic linkup
between the lab and follow-up. The follow-up
program contacts the baby’s family
and physician and does not report the
children to the Special Child Health Services
Registry until a diagnosis is confirmed.
Once the babies with confirmed disorders
get reported to the Special Child Health
Services Registry, they are referred to
case management. When New
Jersey increased the numbers of conditions
in its newborn screening panel, the program
proportionately increased the number of
staff for the prog ram.
Dr.
Rinaldo mentioned New Jersey is one of
the few States with a law that mandates
metabolic postmortem screening, and asked
whether New Jersey has any plans to involve
the medical examiner’s office and
incorporate data from that office in the
Special Child Health Services Registry.
Ms. Beres-Sochka said, the Special Child
Health Services Registry is working with
the medical examiners, to improve the
process; presently the process is somewhat
slower. Still, the Special Child Health
Services Registry does review all death
certificates of children under age 3 and
requests autopsy reports from birthing
facilities.
Dr.
Boyle asked whether New Jersey’s
Special Child Health Services Registry
has data on long-term follow-up of children
found to have disorders. Ms. Beres-Sochka
said New Jersey does not currently have
the ability to do long-term follow-up
but is at a preliminary stage in developing
that capacity, using money from CDC.
Committee
Business: Setting Committee Priorities:
Overview
Peter van Dyck, M.D., M.P.H.
Associate Administrator
Maternal and Child Health Bureau
Health Resources and Services Administration
(HRSA)
Dr.
van Dyck briefly explained Federal guidelines
governing the formation and operation
of subcommittees of federally established
committees, such as this Committee:
The
chair of such a Committee,—in the
case of this Committee, Dr. Howell—generally
has the discretion to establish whatever
subcommittees he or she wants. Subcommittees
are established with members of the committee.
The Chair is responsible for appointing
a chair of each subcommittee and may assign
committee members to staff subcommittees.
Subcommittees
do their work both between and during
meetings. Thus, a subcommittee can get
an assignment and work on the assignment
by conference call, which MCHB staff will
help facilitate, and then report on its
work at full Committee meetings. The staff
will assist with research or items that
subcommittees need between Committee meetings
to develop their material. If a subcommittee
absolutely must meet face-to-face over
a very difficult issue or for some other
reason, MCHB can facilitate and help pay
for that subcommittee meeting. Regular
minutes of subcommittee meetings should
be taken, and when subcommittees report
to the full Committee, their reports are
part of the official record.
At
the discretion and invitation of the Committee
Chair, individuals from the community
or with special expertise may be invited
to present to a subcommittee, contribute
special expertise, or even join a subcommittee.
At the discretion of the Chair and the
staff, a consultant could be asked to
write a paper or do some other task for
a subcommittee. The activities can be
paid from the Committee budget.
Dr.
van Dyck also explained that subcommittees
last only as long as it takes them to
perform a task. Once a subcommittee’s
task is completed, the subcommittee can
disband. Presumably, at that point, a
new subcommittee would be established
Setting
Committee Priorities: Discussion
R. Rodney Howell, M.D.
Chair, Secretary’s Advisory Committee
on Heritable Disorders and
Genetic Diseases in Newborns and Children
Resuming
Committee business, Dr. Howell said that
he would like Committee members to decide
how many subcommittees the Committee should
establish (with two to three Committee
members on each subcommittee) and what
those subcommittees should address. He
added that he also would like to get people’s
preferences for specific subcommittees.
Dr. Howell’s impression is that
subcommittees are responsible for forming
their own agenda and work plan. A spokesperson
for each subcommittee will present the
subcommittee’s plan of action at
the April 2005 meeting of the full Committee
before the subcommittee starts doing any
work. (Dr. Howell subsequently modified
this plan to expedite the process, as
discussed below.)
As
a framework for coming up with the specific
subcommittees, Dr. Rinaldo suggested that
the Committee initially use the pyramid
of four “core public health services,”
Dr. van Dyck showed in his presentation
earlier (Tab #11 in the notebook distributed
to Committee members):
Direct
health care services (e.g., basic
health services and services for children
with special health care needs;
Enabling
services (e.g., transportation, translation,
outreach, respite care, family support
services, case management, coordination
with Medicaid and Federal maternal and
child health programs);
Population-based
services (e.g., screening, counseling,
immunization, nutrition, public education);
and
Infrastructure-building
services (e.g., needs assessment,
evaluation, planning, policy development,
coordination, quality assurance, standards
development, monitoring, training, applied
research, systems of care, and information
systems).
Committee
members made additional suggestions for
subcommittee consideration: the challenges
States are going to face in adopting the
newborn screening panels recommended in
the ACMG report; inclusion of two areas
to address infrastructure: information
technology and financing; longer-term
issues, such as the criteria for additional
selection of newborn screening tests and
quality improvement; and education and
training (i.e., professional training
and parent education). After discussion,
the Committee arrived at three subcommittees
with the inclusion of several topics,
along with several crosscutting issues:
LABORATORY
STANDARDS AND PROCEDURES (e.g., lab
standards, including case definitions/cutoffs—a
high priority; quality improvement; residual
blood spots);
EDUCATION
AND TRAINING (e.g., education of parents
and consumers, public education, health
professional training); and
TREATMENT
AND FOLLOW-UP (e.g., treatment protocols,
evaluation of new treatments, reimbursement).
The
crosscutting issues identified
by the Committee as being of importance
to all three of the proposed subcommittees
were (a) evaluation of technology/tests/conditions
(methodology and criteria); (b) information
technology; and (c) financing.
To
end the discussion, the Committee unanimously
approved the following motion related
to the establishment of subcommittees
for the Advisory Committee on Heritable
Disorders in Children and Newborns:
MOTION
#1: The Committee shall have the following
three subcommittees: (1) LABORATORY STANDARDS
& PROCEDURES (which includes new technology
and the addition of new tests); (2) EDUCATION
& TRAINING; and (3) TREATMENT &
FOLLOWUP. The crosscutting issues of evaluation,
information technology, and financing
should be considered by each subcommittee.
Each subcommittee is to develop an agenda
and work plan.
Public
Comment Section
Dr.
Singh, noting that many children diagnosed
by newborn screening are treated by immediate
nutrition interventions, emphasized the
urgency of training metabolic dietitians
as genetics team members who can affect
outcomes for children born with these
disorders. She believes that well-trained
dietitians can contribute in the area
of research, as well as in clinical practice.
Dr. Singh thanked the HRSA for funding
a pilot grant program for needs assessment
for continuing education needs for nutrition
professionals. She also urged efforts
to ensure adequate third-party reimbursement
for treatment of persons affected with
metabolic disorders, particularly adults.
Dr. Singh and others are in the process
of establishing a formal organization
for metabolic dietitians, and she feels
confident that group would be willing
to assist the Committee on issues of interest.
Carol
Greene, M.D.
Society for Inherited Metabolic Disorders
(SIMD)
and (2) efforts to ensure the availability
of adequate resources for successful newborn
screening. SIMD and its members are eager
to help the Committee in any way they
can.
Jill
Fisch
Parent & National Director of
Education and Awareness
Save Babies Through Screening Foundation
(SBTS)
Ms.
Fisch made five key points in her statement.
First, she thanked the Committee and other
agencies working to move newborn screening
in a forward and positive manner, noting
the importance of collaboration among
various agencies and organizations. Second,
she said that although several States
have recently added disorders to their
newborn screening programs, there remain
States that have made no move to expand
their programs—she hopes that the
Committee’s work will help change
this situation. Third, Ms. Fisch underscored
the need for a national database in place
to follow patients with these disorders
and their response to treatment and the
importance of having all States report
their data to the National Newborn Screening
and Genetics Resource Center. Fourth,
she stressed the importance of educating
health professionals about heritable and
genetic disorders and increasing the number
of physicians who specialize in metabolic
disorders. She believes that once the
health care professionals are educated,
parents can become educated through their
doctors. Fifth, she expressed concern
about the financial situation of metabolic
centers in New York and said she would
appreciate any guidance that the Committee
might offer on how to help the centers
obtain adequate funding. Ms. Fisch closed
by thanking the Committee for its support
and efforts.
Jana
Monaco
Parent & Board Member
Organic Acidemia Association
Ms.
Monaco—who has a son with has severe
brain damage due to late diagnosis of
isovaleric academia and a daughter who
is healthy because of early detection—noted
that States increasingly are aware of
the fact that they need to make changes,
but babies with metabolic disorders are
still dying or suffering because their
disorders are not detected and treated
early. Recommending a universal panel
of newborn screening tests, therefore,
is just the first step in a long process
to ensure effective testing and treatment
of babies with metabolic disorders. Ms.
Monaco urged the Committee to involve
parents and organizations like hers in
efforts to help raise awareness, support
research, educate professionals, and implement
long-term follow-up of babies found to
have metabolic disorders. She closed by
thanking the Committee on behalf of the
Organic Acidemia Association for moving
forward to develop a universal newborn
screening program that will reduce disparity
among States and ensure quality and effective
testing and treatment for babies and children
in the United States.
William
Slimak
Vice President of Operations
Pediatrix Screening
Pediatrix Medical Group
Mr.
Slimak noted that he would be making a
statement for Pediatrix in place of Philip
Vaughn, M.D., who had laryngitis. Mr.
Slimak stated that Pediatrix Medical Group
is a leader in hearing screening and metabolic
screening and was instrumental in developing
tandem mass spectrometry. Pediatrix believes
that the American College of Medical Genetics
report on newborn screening is important
to adoption of broader scope of screening
services and is pleased that it is about
to be made available to the Secretary
of Health and Human Services and the public.
Pediatrix has operational, clinical, and
technical expertise related to newborn
screening and hopes that it can contribute
to the work of the Advisory Committee
on Heritable Disorders and Genetic Diseases
in Children and Newborns and its subcommittees.
Micki
Gartzke
Parent &
National Director of Education and Awareness
Hunter’s Hope Foundation
Ms. Gartzke thanked the Committee and
its partners for their hard work and commitment.
She noted that the Hunter’s Hope
Foundation, which started in 1997 with
a mission to increase public awareness
of Krabbe disease and other leukodystrophies,
is now committed to working to ensure
that all babies born in the United States
receive newborn screening for all the
diseases for which tests are available.
Ms.
Hooker noted that the Mountain States
Genetics Network is one of the new Regional
Genetics and Newborn Screening Collaboratives
being funded by HRSA—specifically,
the Region 6 Genetics Collaborative Center
(which covers Arizona, Colorado, Montana,
New Mexico, Texas, Utah, and Wyoming).
One of the most important and productive
activities of regional networks, Ms. Hooker
said, is providing the opportunity to
network, because networking—whether
formal or informal—is the first
step to collaboration and the coordination
of services. The Mountain States Genetics
Network is committed to providing opportunities
for face-to-face networking. Ms. Hooker
ended by saying she hopes that the Committee
will regard the Regional Genetics and
Newborn Screening Collaboratives as a
knowledgeable and fervent resource.
Peter
Sybinsky, Ph.D.
Chief Executive Officer
Association of Maternal and Child Health
Programs (AMCHP)
Dr.
Sybinsky began his statement by explaining
that AMCHP represents State and territorial
public health leaders who administer statewide
programs to improve maternal and child
health. Testing newborns for metabolic
disorders, Dr. Sybinsky said, is essential
to giving every child a strong start in
life. As the Committee moves forward with
its work, AMCHP urges it to recognize
that effective newborn screening is more
than just testing—it is an entire
system that includes parent and doctor
education, medical referrals and follow-up,
and ongoing support for a child’s
medical care. AMCHP also urges the Committee
to recommend the provision of adequate
Federal resources to support State newborn
screening systems. Although States rely
significantly on the fees charged to families
or hospitals to finance testing and laboratory
costs, the Maternal and Child Health Block
Grant usually pays for follow-up services
and specialty care when it is not available
through Medicaid, the State Children’s
Health Insurance Program, private insurance,
or other sources of funding. For that
reason, AMCHP calls on the Committee to
recommend adequate funding for these programs.
Dr. Sybinsky concluded by saying that
AMCHP thanks the Committee for its efforts
and looks forward to providing any assistance
to the Committee that it can.
R.
Rodney Howell, M.D.
Chair, ACHDGDNC
Dr.
Howell made the following assignments
to subcommittees, with individual preferences
taken into account.
SUBCOMMITTEE
ASSIGNMENTS |
LABORATORY
STANDARDS & PROCEDURES
Chair: Dr. Brower
Members: Dr. Alexander, Dr. Coggins,
Dr. Rinaldo and Dr. Howell
|
EDUCATION
& TRAINING
Chair: Dr. Howse
Members: Dr. Edwards, Dr. Becker,
Dr. Hawkins, and Dr. Collins |
FOLLOWUP
& TREATMENT
Chair: Dr. Boyle
Members: Dr. van Dyck, Dr. Dougherty,
Mr. Robertson, and Dr. Telfair |
Committee
discussion noted that if the subcommittees
worked on their agendas at the April 2005
meeting, there would be no subcommittee
work in the interim period. Dr. van Dyck
laid out a proposal to have subcommittee
agendas reviewed and approved electronically
in the interim. As Chair, Dr. Howell could
specify that the subcommittees are to
form an agenda within 30 days, for example.
Upon receiving the subcommittees’
proposed agendas, the staff at MCHB could
e-mail them out to the full Committee,
and there could be a comment period of
a week or some other period. Once the
Chair approved a subcommittee’s
agenda, he would notify the subcommittee
of his approval to proceed with its work.
Dr. Howell agreed that communicating by
phone and by e-mail to expedite the review
of the subcommittees’ agendas was
a good idea and told Committee members
to submit their agendas or actions plans
by the end of February.
- Crosscutting
issues. The Committee should flush
out the crosscutting issues that are
to be addressed by the subcommittees—i.e.,
evaluation, information technology,
and financing. Outside experts could
be invited to talk about these issues.
Dr. Howell said that Dr. Lloyd-Puryear
could start working on inviting experts/speakers.
Committee members should let Dr. Howell
know if they have people they want to
recommend.
- American
College of Medical Genetics (ACMG) report
on newborn screening. An agenda
item for the Committee’s next
meeting and subsequent meetings is a
continuing status report on the ACMG
report on newborn screening produced
for HRSA. By April, the report will
have been released to the public. Dr.
Howell agreed that having a report update
as an agenda item would be appropriate.
Dr. van Dyck said that MCHB staff would
be happy to report on the status of
the report at each meeting. Discussion
indicated that ACMG Executive Director,
Michael Watson, Ph.D., be invited to
present on those aspects of the report
that the Committee hasn't already considered,
along with the report’s recommendations.
Dr. Boyle reminded Committee members
that they had voted on several motions
pertaining to the report on the previous
day.
- Legal
issues related to newborn screening.
Dr. Rinaldo and Dr. Edwards suggested
that perhaps the Committee should pay
some attention to the legal issues related
to newborn screening programs. Dr. Howell
thought the Committee could benefit
from having consultants speak on legal
issues relevant to newborn screening.
Given the many items already on the
suggested agenda for the April meeting,
Dr. Hawkins suggested that the legal
issues be deferred for a subsequent
meeting; in the interim, the three new
subcommittees could start making a note
of important legal issues and give them
to Dr. Howell. Dr. Howell agreed that
this approach would be helpful.
- Research.
Dr. Rinaldo suggested research as
an agenda item for later. Dr. Howell
said that as the subcommittees work
toward some of the immediate solutions,
areas where the knowledge is incomplete
will be evident. That will obviously
suggest a great research agenda.
Dr.
Howell reminded members of the public
that it is important to let the Committee
know in advance that they are coming to
make a public statement. It is also helpful
if they submit a written statement to
ensure that their statement is accurate
in the record.
The
next three Committee meetings, Dr. Howell
noted, are scheduled for the following
dates, and all will be held in the Rotunda
Ballroom, 8th floor of the Ronald Reagan
Building and International Trade Center,
Washington, DC:
-
April 21-22, 2005
-
July 21-22, 2005
-
October 20-21, 2005
Dr.
Howell said that Committee members should
consider that the aforementioned dates
are firm. Dr. Howell thanked the members,
speakers, and audience members for participating,
and concluded the meeting.
We
certify that, to the best of our knowledge,
the foregoing meeting minutes of the Advisory
Committee on Heritable Disorders and Genetic
Diseases in Newborns and Children are
accurate and correct.
/s/
R.
Rodney Howell, M.D
ACHDGDNC, Chair
/s/
Michele
A. Lloyd-Puryear, M.D., Ph.D.
ACHDGDNC, Executive Secretary
These
minutes will be formally considered by
the Committee at its next meeting, and
any corrections or notations will be incorporated
in the minutes of that meeting.
Committee
Members Present:
R.
Rodney Howell, M.D.
Committee Chairperson
Professor
Department of Pediatrics
The University of Miami School of Medicine
P.O. Box 016820
Miami, FL 33101
Duane
Alexander, M.D.*
National Institutes of Health
Director
National Institute of Child Health and
Human Development
31 Center Drive, Room 2A03
Mail Stop Code 2425
Bethesda, MD 20892-2425
William
J. Becker, D.O., M.P.H.
Medical Director
Bureau of Public Health Laboratories
Ohio Department of Health
1571 Perry Street, P.O. Box 2568
Columbus, OH 43216-2568
Coleen
Boyle, Ph.D., M.S.*
Centers for Disease Control and Prevention
Associate Director
Science and Public Health Team
1600 Clifton Road, Mailstop E87
Atlanta, GA 30333
Amy
Brower, Ph.D.
Third Wave Technologies
502 S. Rosa Road
Madison, WI 53719
Peter
B. Coggins, Ph.D.
Senior Vice President
PerkinElmer
President
PerkinElmer Life and Analytical Sciences
549 Albany Street
Boston, MA 02118
Denise
Dougherty, Ph.D. *
Agency for Healthcare Research and Quality
Senior Advisor, Child Health
540 Gaither Road
Rockville, MD 20850
E.
Stephen Edwards, M.D., F.A.A.P.*
American Academy of Pediatrics
Past-President
2700 Conover Court
Raleigh, NC 27612
Gregory
A. Hawkins, Ph.D.
Assistant Professor
Department of Internal Medicine
Center for Human Genomics
Wake Forest University School of Medicine
Medical Center Boulevard
Winston-Salem, NC 27157-1054
Jennifer
L. Howse, Ph.D.**
March of Dimes Birth Defects Foundation
1275 Mamaroneck Avenue
White Plains, NY 10605
Piero
Rinaldo, M.D., Ph.D.
Professor of Laboratory Medicine
Mayo Clinic College of Medicine
Department of Laboratory Medicine and
Pathology
Chair, Division of Laboratory Genetics
Mayo Clinic Rochester
200 First Street, S.W.
Rochester, MN 55905
Derek
Robertson, J.D., M.B.A.
Attorney-at-Law
Powers, Pyles, Sutter & Verville,
PC
1875 Eye Street, NW, 12th Floor
Washington, DC 20006-5409
Joseph
Telfair, Dr.P.H., M.S.W., M.P.H.**
Secretary’s Advisory Committee
on Genetics, Health and Society
Department of Maternal and Child Health
School of Public Health
University of Alabama at Birmingham
1665 University Boulevard, Room 320
Birmingham, AL 34294-0022
Peter
C. van Dyck, M.D., M.P.H.*
Health Resources and Services Administration
Associate Administrator
Maternal and Child Health Bureau
U.S. Department of Health and Human Services
Parklawn Building
5600 Fishers Lane, Room 18-05
Rockville, MD 20857
*Ex
officio member.
**Liaison
member.
ACHDGDNC
Staff:
Michele
A. Lloyd-Puryear, M.D., Ph.D.
Health Resources and Services Administration
Committee Executive Secretary
Chief, Genetic Services Branch
Maternal and Child Health Bureau
U.S. Department of Health and Human Services
Parklawn Building
5600 Fishers Lane, Room 18A-19
Rockville, MD 20857
APPENDIX
A: WRITTEN PUBLIC COMMENTS
- Rani
Singh, Ph.D., R.D.—Genetic Metabolic
Dietitian
-
Carol Greene, M.D.—Society for
Inherited Metabolic Diseases [statement
read by Judith Tuerck, R.N., M.S]
- Jill
Fisch—Parent & National Director
of Education and Awareness, Save the
Babies Through Screening Foundation
- Jana
Monaco—Parent & Board Member
of the Organic Acidemia Foundation
-
William Slimak, Vice President of Operations,
Pediatrix Screening, Pediatrix Medical
Group
- Micki
Gartzke—Parent & Director
of Education and Awareness, Hunter's
Hope Foundation
- Joyce
Hooker—Executive Director, Mountain
States Genetics Network
- Peter
Sybinsky, Ph.D.—Chief Executive
Officer, Association of Maternal and
Child Health Programs
Rani
Singh, Ph.D., R.D.
Genetic Metabolic Dietitian
Statement to the Advisory Committee on
Heritable Disorders and Genetic Diseases
in Newborns and Children
January
14, 2005
Mr.
Chairman:
Thank
you for this opportunity to speak as a
metabolic dietitian. I want to open my
comments by acknowledging that a majority
of the diseases diagnosed by Newborn Screening
(NBS) recommended by the American College
of Medical Genetics (ACMG) panel are treated
by immediate nutrition interventions.
Therefore, the qualifications and the
role of a metabolic dietitian as a genetics
team member can have a great impact on
the outcome of these children. I wanted
to emphasize the urgency for the need
to train and support dietitians in the
field. (I was very excited to note Nutritionist
clearly listed under Direct Services in
Peter Van Dyck’s presentation.)
This
becomes even more critical in the face
of shortage of biochemical geneticists
while expanding newborn screening. I have
created an International List-Serv for
metabolic dietitians and now we have close
to 200 members. Participating members
continuously express confusion with treatment
protocols and lack of understanding with
the standards of care which lack evidence-based
research and treatment protocols. I feel
well trained dietitians cannot only contribute
in clinical practice but also in the area
of research.
I
also want to thank HRSA for funding a
pilot grant in Region 3 for needs assessment
for CE (continuing education) needs and
development of the first educational module
for nutrition professionals. I do want
to take this opportunity to urge that
efforts to assure availability of qualified
dietitians in the metabolic centers and
the adequacy of nutrition resources like
medical foods and low-protein foods are
available for treatment. Lack of third
party reimbursement continues to threaten
the availability of treatment in some
States for affected persons particularly
those who have now entered adulthood.
We
are in the process of establishing a formal
organization for metabolic dietitians
to meet our needs and feel confident that
group would be willing to assist the committee
with any efforts focused in this direction.
Carol
Greene, M.D.
Society for Inherited Metabolic Disorders
Statement to the Advisory Committee on
Heritable Disorders and Genetic Diseases
in Newborns and Children
January
13-14, 2005
Thank
you, Mr. Chairman, for the opportunity
to speak, and thank you to the Committee
for your efforts on behalf of those with
inborn errors of metabolism and other
genetic disorders.
The
Society for Inherited Metabolic Diseases
(SIMD) is dedicated to improving scientific
and public understanding about inborn
errors of metabolism, and to promoting
advances in the identification and care
of those affected by inborn errors of
metabolism. Members of the SIMD are scientists,
physicians, nutritionists, nurses and
other health professionals working in
patient care and in research, in the laboratory
and in the clinic, in academia, in public
health, in private medical systems and
in the biotechnology industry.
SIMD
members provide diagnostic and treatment
services to individuals of all ages with
inherited metabolic disease to minimize
the risks of disability and death. SIMD
members play a prominent role in the diagnostic
follow-up and treatment of children detected
by newborn screening with inborn errors
of metabolism. From this perspective,
we very much appreciate your endorsement
of the report “Newborn Screening:
Toward a Uniform Screening Panel and System”
at your last meeting, and we support your
efforts to expand newborn screening. We
understand from presentations at your
meeting that this endorsement is an important
step along a path to expanding the panel
of conditions for which newborns in the
United States are screened, and to do
so with uniformity. We look forward to
reviewing this report when it is available
for public comment. In the meantime, we
wish to take this opportunity to urge:
-
Expeditious efforts to assure that newborn
screening panels across the country
are rapidly expanded to identify children
with treatable inborn errors of metabolism.
-
Efforts to assure availability of adequate
resources for successful newborn screening
and follow-up. The diagnosis of a biochemical
genetic disease in an infant detected
through newborn screening should be
confirmed in a qualified diagnostic
laboratory, and immediate and long-term
treatment should be available from qualified
and experienced experts in inborn errors
of metabolism. Mechanisms need to be
in place to adequately fund all aspects
of newborn screening, and to fund the
treatment of inborn errors of metabolism
in those who are identified by newborn
screening. Funding needs to be assured
for education, testing, reporting of
results, confirmation of abnormal screening
results, diagnosis, comprehensive long-
term treatment and evaluation of patients,
and outcomes evaluation of newborn screening
programs and practices.
Again
we thank you for this opportunity to speak,
and want to assure the Committee that
the SIMD and its members are eager to
help you in your efforts on behalf of
the people we both serve.
Jill
Levy Fisch
National Director of Education and Awareness
Save Babies Through Screening Foundation
Public Comments
January
14, 2005
Good
afternoon. It is a pleasure to be here
today and an honor to have the opportunity
to address the committee.
My
name is Jill Fisch. I am the National
Director of Education and Awareness for
the Save Babies Through Screening Foundation.
I would like to acknowledge and say thank
you to the committee and other agencies
that are hard at work to move newborn
screening in a forward and positive manner.
Collaboration
between various agencies and organizations
is essential. Newborn screening is not
just an issue of the actual screening
and gives rise to other issues which need
to be addressed. Some of the issues are
education, financing, data collection,
evaluations and infrastructure. Other
issues of great importance are linking
identified children to services, ancillary
services, manpower, money for treatments
and parental difficulties.
Some
states are finally paying attention to
newborn screening. Since the last meeting,
Alabama, Connecticut, Louisiana, Michigan,
Minnesota, New York, South Carolina, North
Carolina and Georgia have added disorders
to their programs. New York will be screening
for all disorders by the spring and Florida
is going to begin adding disorders in
February for a total of 25 added by the
end of 2005. It is truly wonderful to
see such progress being made. However,
there are states where there is no move
to expand and it is my hope that upon
Secretary Thompson’s acceptance
of this committee’s recommendations
that things will change. For those viewing
this issue from a financial perspective
versus quality of life Colorado’s
newborn screening states that “identifying
just two cases of PKU and 12 cases of
hypothyroidism this year will save $2.5
million in lifetime costs for institutional
care and special education.” Delaware’s
states that “newborn screening,
together with rapid diagnosis and treatment
prevents mental retardation, illness,
and death in newborns. It also saves millions
of dollars in treatment, home and institutional
cost. For every $1 spent on newborn screening,
$9 in medical care and treatment costs
are saved—resulting in a national
savings of $36 million every year.”
Since the last meeting approximately 530
unscreened babies with disorders have
been born. I now view these babies as
ticking time bombs. Time is of the essence.
There
has been much discussion regarding the
efficacy of treatment of certain disorders.
One of these debated disorders, SCADD,
has greatly affected my family. I have
seen first hand that treatment can be
effective. My father has been receiving
treatment for several months and is finally
able to manage the stairs in his home
without difficulty. We need to have a
national database in place to track patients
with these disorders and their response
to treatment. This is the only way we
will be able to see what treatments are
effective. All states should be reporting
their data to the National Newborn Screening
and Genetics Resource Center, so that
needs are easily identified and support
can be given. I am not quite sure I understand
why NY is the only state in the country
that refuses to produce their data. This
concerns me, greatly. I am hopeful someone
on the committee can help me understand
why this is occurring.
SCADD
Family
Jana Monaco
Parent & Board Member of the Organic
Acidemia Foundation
Public Comments
January
14, 2005
Good
afternoon and thank you again for the
opportunity to come and speak on behalf
of Expanded Newborn Screening. I am the
parent of two children with Isovaleric
Acidemia, Stephen with severe brain damage
due to late diagnosis and Caroline who
is a healthy normal two year old thanks
to early detection. I wish to thank each
of you for the dedication that you have
committed to NBS. We are all aware of
the fact that it has not been an easy
process, but you have diligently worked
to finally get a report completed and
prepared to send to the Secretary. The
mere fact that a report is coming has
helped move things along in the state
of Virginia as well as other states.
As pointed out yesterday, states are aware
of the fact that they need to make changes
and Virginia is moving in that direction.
With all due respect, as the parent of
a child severely disabled due to lack
of Comprehensive NBS, I have to disagree
with Mr. Ross’ statement from yesterday,
stating that our NBS program is a highpoint
in the American medical system. If it
was, we wouldn’t be here today.
It’s good but far from stellar.
It no doubt teaches us that we have a
long way to go. A recent example of this
important fact is a baby names Joseph
in Norfolk, whose grandmother has connected
with me to share his story and seek advice.
He is a 4-month-old baby diagnosed 3 ½
weeks ago with MMA. His diagnosis came
after weeks of visits to the pediatrician
with concerns only to be brushed off and
attributed to the concerns of a young,
single mother. Their lack of health insurance
also played a role in the lack of urgency
with his care. Like Stephen, Joseph has
been on a ventilator and the family has
been told to consider turning off life
support.
Over
the past few months, I have spoken to
the Virginia Genetics Advisory Committee,
and a local town hall meeting which has
helped Virginia adopt bills in the House
and Senate to expand Newborn Screening,
to be consistent with the panel recommended
by the American College of Medical Genetics,
in the soon to be released report. The
regulations must include follow-up and
referral protocols and necessary provisions
to implement the NBS program and any services
available to the infants through the Children
with Special Health Care Needs Program.
To help support the bill, I have been
asked to speak and share my children’s
story at the General Assembly sessions
when the bills are read. I also had the
privilege of speaking at the Northern
Virginia Pediatric Society lecture in
November. This was a great opportunity
to educate physicians who are not up to
speed with these disorders. In all of
my efforts, I have learned that people
do want to know about this subject and
help bring about the necessary changes
to provide our country’s children
with a healthy start in life. It just
isn’t acceptable to continue to
hear medical personnel admit that they
know little about inborn errors of metabolism.
The emphasis should be on education in
this process of expanding NBS. It should
be the number one priority in your subcommittee
development. Each time one of our children
is hospitalized, we parents educate one
more medical staff person on these disorders.
Recommending this universal panel is just
the first step in a long process. Like
me, other parents around the country are
committed in their own states to help
this process.
Although
I am not someone of your professional
expertise, I do have more hands on experience
with living with these disorders like
the rest of us parents. This brings with
it, a parent perspective on the subject
that is vital in the development of this
Newborn Screening program. Various models
already exist within the health sector.
The concept of some sort of data base
or communication system for health care
professionals is a critical component
as well. There is such a concern regarding
privacy issues, but I can assure you that
we lost our privacy the day Stephen went
into crisis. When Stephen was first diagnosed,
we had requested information about Isovaleric
Acidemia. The physician tried to provide
us with what she could to include some
cases of IVA to read. They were old cases
off the internet and did not provide us
with much in the way of understanding
the prospects of a life with IVA. It wasn’t
until we were connected with the Organic
Acidemia Association that we learned a
great deal about IVA. That is where we
discovered that Stephen was not the only
one diagnosed beyond the newborn period
and that there were older IVA children
and adults living with IVA. This is where
follow-up information can be very useful
in education. We were introduced to other
families who had a great deal of information
to share with us in regards to raising
a child with an inborn error of metabolism…
information that we did not receive from
the physicians. As you form your subcommittees
and seek to find ways to do long term
follow-up and possibly develop informational
data bases, use us parents in some sort
of capacity. Our organizations are full
of parents willing to help raise awareness,
support research, and provide assistance
with educating others. Many come with
their own level of professional expertise
that compliments our organizations. We
are a place to begin this aspect of the
NBS process as well as other components
of the process. We are people that take
initiative in case you haven’t already
noticed, and have already relinquished
a level of privacy for the sake of NBS
and to connect with others. My husband
and I along with three other IVA families
have developed a called IVASupport.org
whose goal is to be an outlet and resource
solely for families of already diagnosed
and newly diagnosed IVA children. It contains
stories and photos of children with IVA,
a detailed definition of IVA, NBS information
articles and studies on IVA by physicians,
and a physician and dietitian on board
for questions. We have provided a letter
to our metabolic clinics and pediatricians
to share with any new IVA families. As
a parent, this is something that I wish
had been available to us upon Stephen’s
diagnosis. This is just an example of
how resourceful parents can be. Again,
I stress that you utilize us. We are a
great resource for understanding the needs
of raising children with inborn errors
of metabolism and have much to contribute.
In
closing, I speak for the Organic Acidemia
Association in thanking you for moving
forward to develop a Universal Newborn
Screening Program that will reduce disparity
among states and ensure quality and effective
testing and treatment for babies and children
in the United States.
William
S. Slimak
Vice President of Operations
Pediatrix Screening
Public Comments
January
14, 2004
Dr.
Puryear, Secretary to the Advisory Committee
on Heritable Disorders and Genetic Diseases
in Newborns and Children (ACHDGDNC)
Following
public comment submitted on January 14th
to the ACHDGDNC meeting by Bill Slimak,
Vice President of Operations, Pediatrix
Screening
Members
of the Committee and other attendees,
thank you for the opportunity to address
you today. My name is Bill Slimak, Vice
President of Operations at Pediatrix Screening.
Qualifications
– extensive background in healthcare
operations….Clinical Chemist by
training – over 30 years of Pharmaceutical
Operations – licensed Biologics.
Proud
to be a part of this enterprise where
we can do so much good for future generations.
Pediatrix Medical Group’s mission
is to improve the lives of newborns. Screening
is an important part of that mission.
Pediatrix Medical Group has been a leader
in Newborn Hearing Screening and now Newborn
Metabolic Screening.
Pediatrix
Screening was instrumental in developing
the application of Mass Spectrometry to
Newborn Screening and now has 10 years
and over 2 million babies experience….operationally,
technically and clinically.
Pleased
that the American College of Medical Genetics
report will now be made available to Secretary
and to public. Eagerly anticipate feedback
from the relevant departments and public
at large to help inform future direction.
This will be an important step in encouraging
the adoption of a broader scope of screening
services, through whatever means best
meets the needs of individual programs.
Pediatrix
Screening and Pediatrix Medical Group
anticipate that through our participation
in upcoming subcommittees we will be able
to substantively contribute given our
experience, and the depth and breadth
of expertise:
-
Screening technologies – unparalleled
experience with the combination of technologies
we use today, primary and second tier;
-
Research – Research & Education
continuing to develop future directions
for screening to improve identification
of affected newborns;
-
Data management – vast experience
with developing and managing multifaceted
patient data, 250,000 deliveries/year;
-
Clinical trials – Genetic Counselors
to provide specialty patient communication,
data warehousing, and clinical trials
management experience ideal for development
of future of newborn screening, where
we have a much greater understanding
for the diseases we identify and treat
through newborn screening systems;
-
Standards – We also recognize
the importance of standardization where
possible. Pediatrix Screening actively
participates in important standardization
committees to ensure patient safety,
and build continued confidence and capability
into the advanced technologies used
in newborn screening;
- Operational
control – We have extensive experience
in logistics management, process control
and continuous improvement to ensure
Quality and Efficiency.
In
closing, we have the operational, technical
and clinical expertise to help this committee
in reaching our mutual goals ensuring
that newborn screening is available to
all.
These
issues are complex and states, parents
and primary care physicians will be looking
to all of us in the newborn screening
community to help. To omit Pediatrix Screening
from this process does not further the
goals or mandates of this committee. For
these reasons, we respectfully request
the opportunity to participate as a member
of the proposed subcommittees.
Thank
you again for the opportunity to speak
on this important issue. Pediatrix Screening
looks forward to an increasing our participation
in this process.
Micki
Gartzke
Director of Education and Awareness
Hunter’s Hope Foundation
Public Comments to HHS Advisory Committee
on Heritable Disorders and Genetic Diseases
in Newborns and Children, Ronald Reagan
Center, Washington DC
January
14, 2005
Good
Afternoon Mr. Chairman and Members of
the Committee. Thank you and the many
collaborating agencies and partners for
your work on behalf of children and families
in the U.S. This joint effort is invaluable
to the future of American families. It
is my pleasure and an honor to be able
to share my comments with you today!
My
name is Micki Gartzke, I am the Director
of Education and Awareness for the Hunter’s
Hope Foundation; we are committed to all
children having equal access to all available
newborn screening. Along with the many
thousands of families we work with, who
have gained awareness of the need to improve
NBS on a national basis, we applaud you
for your hard work and commitment towards
fixing this huge national public health
problem.
We
are excited about the progress that will
come with the forward movement of the
American College of Medical Genetics report.
With more and more involvement and greater
partnership on the variety of issues still
to be solved, more children’s lives
will be saved, and that is a great asset
for America!
We
think the priorities for the sub-committees
should be driven, first and foremost,
by what is in the best interests of the
children. And that, right now, is education.
Further resolution of the agenda items
will bring better and faster newborn screening
and consequent follow-up care to children,
and that is what is at stake, providing
effective treatment to those children
identified through newborn screening.
With we expand data collection nationally,
we will find out what’s working
best so we can apply it broadly across
all the states to help health care professionals
do their jobs better. With expanded funding
and funding strategies, equitability will
become a reality and we will realize more
effective treatments. With ALL states
reporting their data to the collective
resource of the National Newborn Screening
and Genetics Resource Center, those states
with needs will be identified. Support
can flow where it is needed. With expanded
infrastructure, opportunities will be
more broadly available linking the children
to the necessary services that are of
the utmost importance in this process.
I continue to hear of children having
6 month waits to see pediatric neurologists.
I continue to hear of medical centers
not having adequate resources to give
the proper care. These issues need to
be fixed so the children can receive the
best care possible. We need to get real
NBS educational information into the hands
of expectant parents so they can ensure
that their newborn is receiving the best
possible option for newborn screening!
We need to engage the obstetric providers
to provide this information. We need to
educate our medical students about newborn
screening. With more education available
at the medical school level, the importance
of the entire newborn screening process
will generate more physicians filling
the service gaps that exist today. This
education can be strongly supported by
partnership, including parents who can
provide real life experiences. I know
that this type of education makes a difference
as I have spoken to many first year medical
school classes on the issue of the pediatric
hospice because of my experience of having
a young daughter needing that valuable
type of care.
Micki
Gartzke
4075 N. Stowell Avenue
Shorewood, WI 53211
(414)332-3238
Testimony
Given Before the Secretary’s Committee
on Heritable Disorders and Genetic Diseases
in Newborns and Children
January
14, 2005
Washington,
D.C.
First
I would like to thank the Genetics Branch
and Hereditary Diseases Program for funding
the regional collaborative centers. I
have been the Regional Coordinator for
the Mountain States Genetics Network since
1985. Over the years the regional genetics
networks produced numerous pamphlets,
brochures, booklets, professional journals
and articles, collected data on newborn
screening and clinical services provided,
conducted surveys, prepared reports and
position papers, created legislation,
and set up clearinghouses for materials
just to name a few items. But the most
important and productive activity has
always been the opportunity to network.
This is the backbone of the Mountain States
Genetics Network now the region 6 genetics
collaborative center.
Networking
can take on many patterns and designs
and is the first step to coordination
and collaboration. For instance, there
is what we refer to as formal and informal
networking: formal being a designated
time and place and informal anytime, anywhere.
It can take place on the phone, Internet,
or via the many telecommunication systems
available. But the most effective and
valuable means of networking is the age-old
face-to-face meeting. Each year the MSGN
asks its members and Annual Meeting attendees
which activity or facet of the MSGN is
the most valuable to them and it is always
the mid year committee meetings and Annual
Meeting. The MSGN has seven multi-disciplinary
committees each on a particular issue.
All committees, whether it is the Consumer
Issues Committee or the Laboratory Practice
Committee, is comprised of consumers,
physicians, genetic counselors, laboratory
staff etc. The MSGN is committed to providing
each committee a full day face-to-face
meeting in the winter and a three-hour
segment at the Annual Meeting in July.
This affords the committee members time
and opportunity to meet and know their
peers and others in the region, to sort
out and discuss issues and problems, to
plan strategies and activities the committee
will carry out and share data and ideas
in a comfortable, non-confrontational
environment. This doesn’t just happen
on its own. It takes commitment and work
from those attending and the staff. But
the benefits are well worth the resources
it takes and we get a big bang for our
bucks. It is important in this great age
of electronic technology and communication
that we not forget the human element.
After all, that is what we are all about.
Again thank you for your generous support
and we hope you will look to the regional
collaborative centers as a knowledgeable
and fervent resource.
Respectively
submitted by,
Joyce Hooker, Executive Director
Mountain States Genetics Foundation/Mountain
States Genetics Network
8129 W. Fremont Avenue
Littleton, CO 80128
Phone: 303-978-0125
Fax: 303-948-1890
Statement
of Peter Sybinsky, Ph.D.
Chief Executive Officer, Association of
Maternal and Child Health Programs
Before the Secretary’s Advisory
Committee on Heritable Disorders and Genetic
Diseases in Newborns and Children
January 14, 2005
Mr.
Chairman and members of the Committee,
I am Peter Sybinsky, CEO of the Association
of Maternal and Child Health Programs.
AMCHP is the national organization representing
state and territorial public health leaders
whose mission is to improve the health
and well being of all women, children
and families, including those with special
health care needs. Our members administer
statewide programs such as newborn screening,
clinics for children with special health
care needs, school-based health centers
and a wide range of other vital health
programs.
I
would like to thank this Committee for
your attention to this critical public
health issue—newborn screening.
Today, I would like to speak with you
briefly on two specific issues:
-
The importance of addressing the entire
newborn screening system, including
follow-up and the key role of state
family health programs, and
-
The need for adequate resources to support
state newborn screening systems.
Testing
newborns for metabolic disorders is essential
to giving every child a strong start in
life. However, effective newborn screening
is more than just testing; it is an entire
system that includes parent and doctor
education, medical referrals and follow-up,
and on-going financial support for a child’s
medical care.
Maternal
and child health agencies help establish
and direct newborn screening systems in
every state. These agencies assure newborns
are screened, provide standards for testing,
notify parents of test results, refer
parents to needed medical services, educate
families and physicians of the implications
of the test results, and conduct long-term
follow-up with families to ensure they
don’t fall through the cracks. Once
a child has been tested, there are still
many activities to carry out to make sure
those with a presumptive positive screen
receive diagnostic testing from a qualified
specialist and then get the services they
need. In Tennessee, for example, the
Maternal and Child Health program ensures
that an infant with a presumptive positive
test receives confirmatory testing, diagnosis
and treatment, if necessary. That process
includes written contact with the parent,
the healthcare provider, a genetic center,
endocrinologist or sickle cell center.
The state program also arranges for any
repeat specimens that may be necessary.
As
the Committee moves forward with its work,
AMCHP urges you to consider all aspects
of state newborn screening systems, not
only the actual blood spot testing but
also the extensive follow-up activities
by the health providers and the state
maternal and child health programs.
The
timeliness and accuracy of testing and
follow-up services can make tremendous
differences in the life of a newborn.
However, we know from Kay Johnson’s
presentation at your previous meeting
that these activities come with a price.
According to the General Accounting Office,
states spent over $120 million on newborn
screening in 2001. Laboratory costs accounted
for 74 percent of states’ expenditures,
and only the remaining 26 percent paid
for follow-up services. Many states rely
significantly on the fees charged to families
or hospitals to cover the testing and
laboratory costs, while the Maternal and
Child Health Block Grant pays for follow-up
services and specialty care when it is
not available through Medicaid, SCHIP,
private insurance or other areas.
As
newborn screening programs expand, someone
will pay for the additional testing and
follow-up. States continue to face budget
limitations and expanding public health
responsibilities. In this environment,
it is difficult for states to maintain
existing services, much less meet the
needs of an expanded screening program.
And it is unrealistic to expect families
to pick up the additional cost of screening.
In all likelihood states will be expected
to pick up these costs.
As
state budgets slowly recover from the
economic downturn, new public health demands
and rising healthcare costs, Federal support
for programs like the block grant and
Medicaid is even more crucial. AMCHP encourages
the Committee to recommend that the Secretary
support increased funding for the Maternal
and Child Health Block Grant in the President’s
budget so that state maternal and child
health programs can meet the increased
needs of newborn screening programs. AMCHP
also calls on the Committee to recommend
full funding of Title XXVI of the Children’s
Health Act of 2000 and increased funding
for CDC’s efforts to help state
newborn screening programs develop integrated
data and surveillance systems. These systems
allowing programs to link data to assist
families to needed follow-up and treatment.
In addition, adequate funding for Medicaid
and SCHIP will be critical to the success
of expanding newborn screening programs.
In
conclusion, AMCHP strongly encourages
this Committee to consider the real cost
of newborn screening programs, including
follow-up activities, and recommend adequate
funding to link all families with the
appropriate care.
The
recommendations of this Committee can
greatly strengthen state newborn screening
systems and maximize the value of the
additional screening tests. AMCHP thanks
you for your efforts and hopes you will
contact us for any assistance we can provide
as you move forward in your work.
Thank
you for the opportunity to provide input
to this important effort.
|